Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Japan’s Envisaged IP Tax Relief Likely to Cover Drug Sales, METI Eyes FY2024 Rollout
Japan’s taxation reform requests for FY2024 embraced the creation of the “innovation box” system that grants a lower tax rate for income generated from intellectual property rights. An industry ministry official recently told Jiho that this scheme is anticipated to…
To read the full story
Related Article
- Deduction Formula for IP Box Tax Relief Now Clear as Preparations Move Ahead
February 22, 2024
- Goals of the “Innovation Box” Tax Break in FY2024 Reform
January 23, 2024
- MHLW Announces “Innovation Box” Tax Regime: FY2024 Reform
December 25, 2023
- Japan OKs FY2024 Tax Reform Outline, “Innovation Box” Scheme Etched
December 15, 2023
- Sales of Patented Drugs to Be Excluded from “Innovation Box” Tax Relief Scheme
December 13, 2023
- Will R&D Tax Credit Be Scaled Back with “Innovation Box” Rollout? Political Settlement Likely
December 8, 2023
- Japan Looks to Launch Innovation Tax Incentive to Ramp Up R&D Investments
August 23, 2023
REGULATORY
- US Calls Out Japan’s Market Expansion Re-Pricing Rules as “Unfair”: IP Report
May 26, 2026
- CEA Review Group Holds First Meeting, Technical Debate Yet to Begin
May 26, 2026
- AstraZeneca’s Oral SERD, MSD RSV Antibody Clear Japan Panel Review
May 26, 2026
- Japan Mulls Target on “Social Security Burden Rate” after CEFP Call
May 25, 2026
- Ishin Deepens Debate on Healthcare Macroeconomic Indexing
May 25, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…